EMERGING TRENDS IN REGULATORY DEVELOPMENTS FOR BIOSIMILARS: RECENT ADVANCES IN GLOBAL AND INDIAN REGULATIONS
Journal Title: International Research Journal of Pharmacy (IRJP) - Year 2012, Vol 3, Issue 8
Abstract
Biopharmaceutical drugs have outperformed the pharmaceutical market as a whole largely due to two factors: they address areas of clinical need that are unmanageable with conventional therapeutics (including cancers) and they are able to command a premium price. With expiry of patent of many biopharmaceutical drugs, the potential of a sizeable market will attract several generic companies. However the process to develop essentially generic version of biopharmaceuticals (biosimilars) is more complex than that of developing a generic copy of a chemical-based compound. These products are approved through an abbreviated route which relies on limited safety and efficacy data enabling the generic companies to keep the production costs low and pass on the price benefit to the patient and make the product affordable to the masses. There are no common regulatory pathways and many countries have published guidelines and it is still evolving in other countries. WHO (World Health Organization), Europe and recently USA have published guidelines for the development and marketing of biosimilar products. These products undergo extensive head to head comparability testing with the reference biopharmaceutical product to show their similarity to the reference product in terms of quality, efficacy and safety. Regulators and administrators of different countries need to strike a balance in cost-to-benefit versus risks that are perceived for these products, keeping in mind global regulatory issues. India's biotechnology industry has been growing towards new heights in conjunction with the economic evolution. The practical way forward for approval of biosimilars in India would have to be unique to the Indian context as it should balance the scientific aspects and consider needs and limitation of the country.
Authors and Affiliations
Kalpesh Shah , Sokindra Kumar
Keywords
Related Articles
- EP ID EP161227
- DOI -
- Views 118
- Downloads 0
EVALUATION OF ANALGESIC AND ANTIDIARRHEAL ACTIVITY OF WHOLE PLANT BOERHAVIA REPENS (FAMILY: NYCTAGINACEAE)
The aim of this study was to evaluate the analgesic and anti-diarrheal activity of the whole plant Boerhavia repens. Sun dried roots, stems, barks and the leaves of B. repens were extracted using methanol at room tempera...
ANTIBACTERIAL ACTIVITY OF THREE PLANT EXTRACTS USED IN NIGERIA FOLKLORIC MEDICINE AGAINST HOSPITAL ISOLATES OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND METHICILLIN-SENSITIVE STAPHYLOCOCCUS AUREUS (MSSA)
Staphylococcus aureus is a species of bacterium commonly found on the skin and/or in the noses of healthy people. Although it is usually harmless at these sites, it may occasionally get into the body (eg through br...
BREAST CANCER RISK FACTORS: PREVENTABLE AND NON-PREVENTABLE
Worldwide, breast cancer comprises 22.9% of all cancers (excluding non-melanoma skin cancers) in women. The incidence of breast cancer is rising in every country of the world especially in developing countries such as In...
EFFECT OF CONTEMPORARY LIFESTYLE AND SOCIOECONOMIC STATUS ON HYPERTENSION IN EASTERN U.P., INDIA
Recent studies have indicated an increasing prevalence of hypertension in rural and urban areas of India. A population-based survey was carried out during Jan-Dec 2012 in eastern U.P., Districts Varanasi, Chandouli, Jaun...
FTIR ANALYSIS FOR SCREENING VARIATION IN ANTIMICROBIAL ACTIVITY OF FRESH AND DRIED LEAF EXTRACT OF RHYNCHOSTYLIS RETUSA: A THREATENED ORCHID SPECIES OF ASSAM, NORTH EAST INDIA
This study was designed to analyze FTIR data to evaluate the role of functional groups in variation of antimicrobial potential of fresh and dried leaf extract of Rhynchostylis retusa a threatened orchid species of Assam,...